4D Path

Executive Summary

4D Path is a US-based biotechnology company pioneering an AI-powered diagnostic platform for oncology. Its core technology, the QPOR™ Platform, leverages digitized H&E-stained biopsy images to quantify cell cycle deregulations and tumor microenvironment dynamics. By predicting patient response to cancer therapy, the platform aims to enable more personalized treatment decisions, potentially improving outcomes and reducing unnecessary side effects. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company operates at the intersection of AI, diagnostics, and oncology, addressing a critical unmet need in precision medicine. Although currently in a private stage with limited public information on funding or revenue, the innovative approach positions 4D Path as a promising player in the computational pathology space. The platform's ability to extract rich quantitative data from standard H&E slides—without requiring additional stains or assays—could significantly enhance clinical workflow efficiency and accessibility. As the field of AI-driven diagnostics rapidly evolves, 4D Path's technology holds potential for broad adoption across oncology indications, contingent on successful validation and regulatory clearance.

Upcoming Catalysts (preview)

• 2026Clinical Validation Study Results65% success
• 2026Strategic Partnership or Licensing Deal50% success
• 2026Series A or Series B Funding Round70% success